Breaking Barriers in Cancer Research: The Sloane Kettering Legacy

A History of Innovation and Excellence

Sloane Kettering Cancer Center has been at the forefront of cancer research for over a century, with a legacy that is unparalleled in the medical community. Founded in 1889 by William Henry Welch and William James Mayo, the institution has consistently pushed the boundaries of what is possible in the fight against cancer.

From its early days as a small hospital to its current status as one of the world's leading cancer research centers, Sloane Kettering has always been driven by a commitment to innovation and excellence. This dedication has led to numerous breakthroughs and discoveries that have improved our understanding of cancer and paved the way for new treatments.

Pioneering Research and Treatment Methods

Sloane Kettering has been instrumental in developing new treatments and therapies that have transformed the landscape of cancer care. From the discovery of the first effective chemotherapy drugs to the development of targeted therapies, the institution's researchers have consistently challenged conventional wisdom and pushed the boundaries of what is possible.

One notable example is the work of Dr. Emil Frei III, who pioneered the use of combination chemotherapy in the 1960s. This groundbreaking approach has since become a standard treatment for many types of cancer.

A Commitment to Patient-Centered Care

At Sloane Kettering, we understand that cancer is not just a medical condition, but also an emotional and psychological challenge for patients and their families. That's why our institution has made patient-centered care a core part of its mission.

From the moment a patient walks through our doors, they are treated with compassion, empathy, and respect. Our team of healthcare professionals works tirelessly to provide personalized treatment plans that address not just the physical aspects of cancer, but also the emotional toll it takes.